Marksans Pharma gets EIR from USFDA for its Goa facility

New Delhi: Drug firm Marksans Pharma said it has received Establishment Inspection Report (EIR) from the US health regulator for its Goa facility.
The company has received EIR from the United States Food and Drug Administration (USFDA) after inspection of its Goa facility from April 3-7, 2017, Marksans Pharma said in a BSE filing.
As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.
EIREstablishment Inspection ReportGoa facilityindian pharma newsinspectionMarksans Pharmapharma newspharma news indiaUSFDA
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd